CTOR: Citius Oncology Inc Price-to-Revenue Coefficient
The P/S ratio of Citius Oncology, Inc. (CTOR) reflects current dynamics, with the latest value recorded as 8.60. Experienced executives are effectively implementing innovative therapy methods. Profit growth is driven by patents for high-margin antineoplastic drugs. Development stability is maintained through the strategic outsourcing of clinical trials to external contractors under strict internal control.
Metric breakdowns and analytics for Citius Oncology, Inc (CTOR)
- market price and analyst price targets:
- market capitalization information:
- company book value details:
- business debt structure and liquidity details:
Total Debt to Capital Citius Oncology, Inc.|CTOR - Long-Term Debt to Equity|Short-Term Debt to Capital Coefficient Citius Oncology Inc|CTOR - Company Total Debt|Debt to Net Assets Ratio Citius Oncology, Inc|CTOR - Company Long-Term Debt|Short-Term Debt Citius Oncology|Immediate Liquidity Ratio citiusonc.com
- earnings and market ratios statistics:
CTOR - Net Profit|Future Profit Citius Oncology, Inc.|CTOR - Price to Earnings Ratio|Projected Price to Earnings Ratio Citius Oncology Inc.|CTOR - Price/Earnings to Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Citius Oncology, Inc|CTOR - Profit before payment of interest, taxes and amortization|Net earnings per one share for the last twelve months Citius Oncology|CTOR - Net earnings per share (EPS TTM)|Net earnings per share growth for the trailing year citiusonc.com|CTOR - Net earnings per share growth this year|Expected net earnings per share growth next year Citius Oncology, Inc.
- issuer revenue and sales details:
Summary company analytics:citiusonc.com, CTOR
The P/S multiple compares market capitalization to revenue, allowing for an assessment of the value of each unit of sales and the identification of market anomalies. For Citius Oncology, Inc. (CTOR), which holds exclusive patented technologies in blood cancer therapy, the price-to-sales multiple reflects the potential for high asset premiums, where the stability of the chart confirms the company's fundamental resilience in the absence of effective market analogues.
Competitors of Citius Oncology, Inc.
Market Cap to Revenue beigene.com ONC|P/S Multiple HALO (Halozyme)|Price-to-Revenue Coefficient Revolution Medicines Inc (RVMD)|AAPG: Market Cap to Revenue|CG Oncology Therapeutics - Market Cap to Sales Volume|URGN: P/S Multiple|BCAX - Price-to-Revenue Coefficient|Market Cap to Revenue PSNL|P/S Multiple Erasca Inc|Price-to-Revenue Ratio Delcath (DCTH)|Price-to-Revenue Coefficient Y-mAbs Corp|Aura Biosciences, Inc. - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio CADL|ARAY - Price-to-Revenue Ratio|Price to Sales SELLAS Life Sciences|Actuate Therapeutics, Inc (ACTU) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio HURA|TARA (Protara Therapeutics) - P/S Multiple|Market Cap to Revenue fatetherapeutics.com (FATE)|Price-to-Revenue Ratio Aadi Bioscience Inc (WHWK)|TCRX - Price to Sales|Price-to-Revenue Ratio Champions Oncology, Inc. CSBR|XBiotech Inc - Price-to-Revenue Ratio|CVM - Price-to-Revenue Ratio|Price to Sales ostherapies.com|RADX: P/S Multiple|Price-to-Revenue Multiple Artiva Biotherapeutics ARTV|Market Cap to Revenue ANL|Price to Sales Veru Corporation VERU|Market Cap to Revenue TPST (Tempest Therapeutics)|XLO (xiliotx.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple RENB (Renovaro)|Price-to-Revenue Coefficient Mural Oncology PLC (MURA)|KAPA - Price-to-Revenue Ratio|OKUR (OnKure Therapeutics Inc) - Market Cap to Revenue Ratio|GDTC: P/S Multiple|Market Cap to Revenue Curis|Market Cap to Revenue APLM|Tharimmune Inc (THAR) - Price-to-Revenue Coefficient|P/S Multiple ADVB|Market Cap to Revenue Genprex Inc GNPX|Calidi Biotherapeutics, Inc. - Market Cap to Revenue|Market Cap to Sales Volume SBFM (sunshinebiopharma.com)|XBIO - Price-to-Revenue Ratio|Price to Sales Salarius Pharmaceuticals Inc|Purple Biotech Corp (PPBT) - Price-to-Revenue Ratio|American Oncology Network, Inc. - Market Capitalization-to-Revenue Ratio|BGNE (BeiGene, Ltd.) - P/S Multiple|Market Cap to Revenue checkpointtx.com (CKPT)|P/S Multiple ELEV|P/S Multiple icadmed.com (ICAD)|Price-to-Revenue Ratio Ikena Oncology IKNA|NTBL: Market Cap to Revenue Ratio|Viracta - P/S Multiple|morphosys.com (MOR) - Market Cap to Revenue|NAYA: P/S Multiple|Price to Sales Ascentage Pharma Group International (AAPGV)
